Evaxion Biotech jumps on U.S. FDA nod for skin cancer therapy study

Evaxion A/S

03/01/2023 13:03

** Shares of drug developer Evaxion Biotech A/S  EVAX.O 
rise 26.2% to $2.24 premarket
    ** Co says it has received approval from U.S. FDA to proceed
with a mid-stage study of its experimental drug, EVX-01, in
combination with Merck & Co's  MRK.N  Keytruda for treating
metastatic melanoma
    ** Melanoma is the most serious type of skin cancer
    ** Co adds that it expects a response by the FDA to its fast
track designation submission for the drug in Q1 this year  
    ** Stock lost ~60% of its value in 2022
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))